Phase 4 Atrial Fibrillation Trial, Recruiting NCT06401616 Sponsor: Odense University Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 4 Atrial Fibrillation Trial, Recruiting

NCT06401616
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have previously had some type of heart surgery that included a procedure to close off a small pouch in the heart called the left atrial appendage (this includes several different surgical techniques or devices, such as the AtriClip), recorded in a Danish national or regional heart or patient registry between January 1st 2010 and up to 3 months before joining the study
  • People with a documented history of an irregular heart rhythm condition called atrial fibrillation or atrial flutter, as recorded in their medical records
  • People who have given their informed consent to take part

Who may not be able to join:

  • People who are not currently taking a blood-thinning medication (such as warfarin or a direct oral anticoagulant, sometimes called a DOAC)
  • People who need to take blood-thinning medication for a separate medical reason, such as having a mechanical heart valve or a previous blood clot in the lungs
  • People with significantly reduced kidney function (confirm with trial site for specific details)
  • People with a known allergy to contrast dye, which is a substance sometimes used during medical imaging scans
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Lars Peter Riber, DMSc, Odense University Hospital

Phone: +4551520696

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Odense University Hospital
Registry
ClinicalTrials.gov
Start date
21 May 2024
Est. completion
1 March 2028

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Number of participants with ischemic strokes, peripheral arterial embolisms and major bleedings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov